<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998669</url>
  </required_header>
  <id_info>
    <org_study_id>20201130</org_study_id>
    <nct_id>NCT04998669</nct_id>
  </id_info>
  <brief_title>Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma</brief_title>
  <official_title>Phase 2, Single-arm, Open-label, Study of Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juan P. Alderuccio, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ADC Therapeutics S.A.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to see if Loncastuximab Tesirine in combination with&#xD;
      Rituximab will result in higher complete response rate when given to treat follicular&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants achieving Complete Response (CR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Complete Response rate will be reported as the number of participants achieving complete response (CR) to study therapy. Response to therapy will be assessed using Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) (FDG-PET)/ Computerized Tomography (CT) following Lugano 2014 criteria by week 12 of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants achieving CR or PR</measure>
    <time_frame>Week 12</time_frame>
    <description>Overall response rate (ORR) will be reported as the number of participants achieving complete response (CR) or partial response (PR) by the end of the induction phase, week 12. Response to therapy will be assessed using Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) (FDG-PET)/ Computerized Tomography (CT) following Lugano 2014 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Related Adverse Events</measure>
    <time_frame>Up to 13 months</time_frame>
    <description>Safety of the intervention will be reported as the incidence of treatment-related toxicity, including serious adverse events (SAEs) and adverse events (AEs), in study participants using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, per physician discretion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Progression-Free Survival (PFS) is defined as the elapsed time from the date of starting treatment (Cycle 1 Day 1) until disease progression or death (whichever occur first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Overall survival (OS) will be defined as the elapsed time from the date of starting treatment (Cycle 1 Day 1) until death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>Loncastuximab tesirine + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the 12-week Induction Phase (Cycles 1 to 4), participants will receive loncastuximab tesirine on days 1 of each 3-week cycle for Cycles 1 through 4; and rituximab on days 1, 8, 15 of Cycle 1 and day 1 of Cycle 2.&#xD;
Maintenance Phase 1 (Cycle 5) is 8 weeks: Participants achieving complete response (CR) or partial response (PR) during the Induction Phase will receive loncastuximab tesirine once every 3-weeks; and rituximab once during week 7 or 8. Participants achieving a response of Stable Disease (SD) or Progressive Disease (PD) will be taken off treatment.&#xD;
Maintenance Phase 2 (Cycles 6 and 7) is 16 weeks:&#xD;
Participants achieving CR during Maintenance Phase 1 receive rituximab once during week 7 or 8 of Cycles 6 and 7.&#xD;
Participants achieving PR during Maintenance Phase 1 receive loncastuximab tesirine once every 3-weeks over each 8 week cycle; and rituximab once during week 7 or 8 of Cycles 6 and 7.&#xD;
Participants achieving SD or PD will be taken off treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loncastuximab tesirine</intervention_name>
    <description>Induction Phase (Cycles 1 through 4):&#xD;
150 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 1 and 2.&#xD;
75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Days 1 of a 3-week cycle during Cycles 3 and 4.&#xD;
Maintenance Phase 1 (Cycle 5): For participants achieving CR or PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines). on Day 1 on Week 1, 4, 7 of a 8-week cycle.&#xD;
Maintenance Phase 2 (Cycle 6 &amp; 7): For participants achieving PR, 75 μg/Kg of loncastuximab tesirine administered via intravenous infusion (given as per treatment guidelines) on Day 1 on Week 1, 4, 7 of a 8-week cycle.</description>
    <arm_group_label>Loncastuximab tesirine + Rituximab</arm_group_label>
    <other_name>ADCT-402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Induction Phase (Cycles 1 through 4): 375 mg/m2 rituximab on days 1, 8, 15 of cycle 1 and day 1 of cycle 2 via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase during Cycles 1 and 2, per discretion of treating physician. Rituximab will not be administered during Cycles 3 and 4.&#xD;
Maintenance Phase 1 (Cycle 5): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 7 or 8 of a 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.&#xD;
Maintenance Phase 2 (Cycles 6 and 7): Participants achieving a response of PR or CR will receive 375 mg/m2 rituximab during week 7 or 8 of each 8-week cycle via intravenous infusion (given as per treatment guidelines) or subcutaneous 1400 mg/23,400 units hyaluronidase, per discretion of treating physician.</description>
    <arm_group_label>Loncastuximab tesirine + Rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women ≥ 18 years of age.&#xD;
&#xD;
          2. Patients must have histologic confirmation of Cluster of Differentiation (CD)19 and&#xD;
             CD20-positive Follicular Lymphoma (FL) (grade 1, 2 and 3A)&#xD;
&#xD;
          3. Patients with relapsed or refractory FL previously treated with ≥1 line of systemic&#xD;
             therapy having ≥ 1 Groupe d'Etude des Lymphomes (GELF) criteria for therapy,&#xD;
             Progression of Diseases within 24 months (POD24), or second relapse.&#xD;
&#xD;
          4. Baseline FDG-PET/CT scans must demonstrate positive lesions compatible with CT defined&#xD;
             anatomical tumor sites. Patients should have at least one measurable site of disease&#xD;
             per Lugano classification.&#xD;
&#xD;
          5. Patient should have ≥ 1 Groupe d'Etude des Lymphomes (GELF) criteria for treatment&#xD;
             initiation).&#xD;
&#xD;
               -  Involvement of ≥3 nodal sites, each with diameter of ≥3 cm&#xD;
&#xD;
               -  Any nodal or extranodal tumor mass with a diameter of ≥7 cm&#xD;
&#xD;
               -  B symptoms (fever ≥ 38 degrees Celsius of unclear etiology, night sweats, weight&#xD;
                  loss &gt; 10% within the prior 6 months).&#xD;
&#xD;
               -  Risk of local compressive symptoms that may result in organ compromise&#xD;
&#xD;
               -  Splenomegaly or splenic lesion without splenomegaly&#xD;
&#xD;
               -  Leukopenia (leukocytes &lt; 1000/mm3)&#xD;
&#xD;
               -  Leukemia (&gt; 5.000 lymphoma cells/mm3)&#xD;
&#xD;
               -  Bone lesions detected on FDG-PET/CT; or&#xD;
&#xD;
          6. Progression or relapsed within 24 months after FL diagnosis in patients previously&#xD;
             treated with ≥1 line of systemic therapy; or&#xD;
&#xD;
          7. Second FL relapse/progression after ≥1 line of systemic therapy.&#xD;
&#xD;
          8. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.&#xD;
&#xD;
          9. Life expectancy of greater than 6 weeks.&#xD;
&#xD;
         10. Patients must have normal organ and marrow function as defined below,&#xD;
&#xD;
               -  Absolute neutrophil count ≥1000/mm3 (unless due to lymphoma involvement of the&#xD;
                  bone marrow or spleen).&#xD;
&#xD;
               -  Platelets ≥100,000/mm3.&#xD;
&#xD;
               -  Hemoglobin ≥ 10 g/dL or ≥8 g/dL in case of bone marrow involvement by lymphoma.&#xD;
&#xD;
               -  Total bilirubin &lt; 1.5 x within normal institutional limits (unless due to&#xD;
                  lymphoma involvement of liver or a known history of Gilbert's disease).&#xD;
&#xD;
               -  Gamma-Glutamyl Transpeptidase (GGT)/Aspartate Aminotransferase&#xD;
                  (AST)/(SGOT)/Alanine Aminotransferase (ALT)(SGPT) ≤ 2.5 × institutional upper&#xD;
                  limit of normal.&#xD;
&#xD;
               -  Creatinine within normal institutional limits, or creatinine clearance ≥40&#xD;
                  mL/min/1.73 m2 for patients with creatinine levels above institutional normal&#xD;
                  (unless due to lymphoma).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. FL grade 3B or transformed FL.&#xD;
&#xD;
          2. Patients with standardized uptake value (SUV) ≥ 14 on FDG-PET/CT and inaccessible&#xD;
             biopsy site.&#xD;
&#xD;
          3. &gt; 2 lines of systemic immunochemotherapy for treatment of FL.&#xD;
&#xD;
          4. Patients with clinically significant pleural effusions and/or ascites requiring&#xD;
             drainage or associated with shortness of breath.&#xD;
&#xD;
          5. Patients receiving any other investigational agents.&#xD;
&#xD;
          6. Patients with known central nervous system involvement of lymphoma.&#xD;
&#xD;
          7. Uncontrolled intercurrent illness such as: history of Myocardial Infarction (MI) in&#xD;
             the last 6 months, congestive heart failure New York Heart Association (NYHA) Class&#xD;
             III-IV, uncontrolled or symptomatic arrhythmia, stroke in last 6 months, liver&#xD;
             cirrhosis, and autoimmune disorder requiring immunosuppression or long-term&#xD;
             corticosteroids (&gt;10 mg daily prednisone equivalent).&#xD;
&#xD;
          8. Breastfeeding or pregnant women.&#xD;
&#xD;
          9. Serologic status reflecting active hepatitis B or C infection. Patients that are&#xD;
             positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or&#xD;
             hepatitis C antibody will need a negative polymerase chain reaction (PCR) prior to&#xD;
             enrollment. (PCR positive patients will be excluded.) Hepatitis C antibody positive&#xD;
             patients are eligible if PCR is negative. Hepatitis B core antibody (+) patients&#xD;
             without evidence of HBsAg or Hep B PCR (+) are eligible with appropriate Hepatitis B&#xD;
             reactivation prophylaxis.&#xD;
&#xD;
         10. Human immunodeficiency virus (HIV) infection.&#xD;
&#xD;
         11. Patients with impaired decision-making capacity.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan P Alderuccio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan P Alderuccio, MD</last_name>
    <phone>305-243-5995</phone>
    <email>jalderuccio@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan P Alderuccio, MD</last_name>
      <phone>305-243-5995</phone>
      <email>jalderuccio@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Juan P Alderuccio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Juan P. Alderuccio, MD</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Loncastuximab tesirine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

